Teriparatide news

Phase III in Japan will evaluate extended teriparatide acetate treatment beyond 24 months for severe osteoporosis patients at high fracture risk, assessing efficacy and safety of continued dosing.

Domestic Phase III trial to assess extended therapy beyond 24 months for patients with severe osteoporosis at high fracture risk; evaluates efficacy and safety of continued treatment.

MAIA will develop and commercialize Teribone™ in the U.S. to address the growing osteoporosis patient population, expanding access to proven bone-forming therapy.

Sales up 6%, net income up 28%, EPS up 30%. Strong growth in Pharma and Closures. $70M returned to shareholders.